Cognition Therapeutics (Cognition Therapeutics) Change In Receivables : $0.75 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cognition Therapeutics Change In Receivables?

Cognition Therapeutics's change in receivables for the quarter that ended in Mar. 2024 was $0.42 Mil. It means Cognition Therapeutics's Accounts Receivable declined by $0.42 Mil from Dec. 2023 to Mar. 2024 .

Cognition Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $2.39 Mil. It means Cognition Therapeutics's Accounts Receivable declined by $2.39 Mil from Dec. 2022 to Dec. 2023 .

Cognition Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cognition Therapeutics's liquidation value for the three months ended in Mar. 2024 was $24.68 Mil.

Cognition Therapeutics Change In Receivables Historical Data

The historical data trend for Cognition Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognition Therapeutics Change In Receivables Chart

Cognition Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-1.12

3.00

-1.11

-1.41

2.39

Cognition Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial													2.06	-0.78	0.76	0.36	0.42

Cognition Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.75 Mil.

Cognition Therapeutics (NAS:CGTX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cognition Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Cognition Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Cognition Therapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	34.671	-	9.991	+	0.75 * 0	+	0.5 * 0
=	24.68

Cognition Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cognition Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cognition Therapeutics (Cognition Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cognition Therapeutics Inc (NAS:CGTX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2500 Westchester Avenue, Purchase, NY, USA, 10577

Website

https://www.cogrx.com

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Executives

John Brendan Doyle	officer: Chief Financial Officer	C/O CHIASMA INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM MA 20494
Lisa Ricciardi	director, officer: CEO & President	C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Anthony Caggiano	officer: Chief Medical Officer	C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Ellen B Richstone	director	C/O SONUS NETWORKS, INC., 7 TECHNOLOGY PARK DRIVE, WESTFORD MA 01886
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Iii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Memory Spv Ii, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Peggy Wallace	director	C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVE., PURCHASE NY 10577
Bios Fund Ii Nt, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107